Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
200.45
+0.09 (0.04%)
Mar 24, 2026, 1:56 PM EDT - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $245.86, which forecasts a 22.65% increase in the stock price over the next year. The lowest target is $220 and the highest is $277.
Price Target: $245.86 (+22.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 5 |
| Buy | 4 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $270 → $276 | Strong Buy | Maintains | $270 → $276 | +37.69% | Mar 24, 2026 |
| B of A Securities | B of A Securities | Strong Buy Initiates $244 | Strong Buy | Initiates | $244 | +21.73% | Mar 11, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $275 → $277 | Buy | Maintains | $275 → $277 | +38.19% | Feb 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $231 → $239 | Strong Buy | Maintains | $231 → $239 | +19.23% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $234 → $235 | Buy | Maintains | $234 → $235 | +17.24% | Dec 10, 2025 |
Financial Forecast
Revenue This Year
272.11M
from 268.09M
Increased by 1.50%
Revenue Next Year
321.85M
from 272.11M
Increased by 18.28%
EPS This Year
8.49
from 6.13
Increased by 38.52%
EPS Next Year
9.81
from 8.49
Increased by 15.56%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 291.9M | 360.5M | |||
| Avg | 272.1M | 321.9M | |||
| Low | 248.2M | 288.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.9% | 32.5% | |||
| Avg | 1.5% | 18.3% | |||
| Low | -7.4% | 5.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 9.19 | 10.70 | |||
| Avg | 8.49 | 9.81 | |||
| Low | 7.29 | 8.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 49.9% | 26.0% | |||
| Avg | 38.5% | 15.6% | |||
| Low | 18.9% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.